(Q24239932)

3

0 references

Karen Cohen

object named as

Karen Cohen

4

0 references

author name string

Tamara Kredo

1

0 references

Jan-Stefan Van der Walt

Cochrane Database of Systematic Reviews

2

0 references

publication date

8 July 2009

0 references

published in

0 references

cites work

A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Concentration-controlled compared with conventional antiretroviral therapy for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)--a randomized controlled trial of therapeutic drug monitoring and adherence support

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapte

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Variable virological outcomes according to the center providing antiretroviral therapy within the PharmAdapt clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Antiretroviral Concentrations in Untimed Plasma Samples Predict Therapy Outcome in a Population with Advanced Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

The role of therapeutic drug monitoring in treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Therapeutic drug monitoring in HIV infection: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

An update on therapeutic drug monitoring for antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Incidence and risk factors for nevirapine-associated rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Treatment of antiretroviral-drug-resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Efavirenz intoxication due to slow hepatic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Practical guidelines to interpret plasma concentrations of antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

New French guidelines for antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

7 January 2021

Pharmacokinetic Parameters of Nevirapine and Efavirenz in Relation to Antiretroviral Efficacy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

7 January 2021

Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

7 January 2021

Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

7 January 2021

Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007268.PUB2

7 January 2021